Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varsetatug masetecan - CytomX Therapeutics

Next Previous
Drug Profile

Varsetatug masetecan - CytomX Therapeutics

Alternative Names: CX-2051; EpCAM PROBODY® ADC; Varseta-M

Latest Information Update: 31 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Developer CytomX Therapeutics
  • Class Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Colorectal cancer; Solid tumours

Most Recent Events

  • 27 Aug 2026 Varsetatug masetecan - CytomX Therapeutics receives Fast Track designation for Colorectal cancer [Parenteral] (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA
  • 07 Aug 2026 CytomX Therapeutics plans a phase I/II trial for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in fourth quarter of 2026 (Parenteral)
  • 18 May 2026 CytomX Therapeutics plans a registrational trial for Colorectal cancer (Second-line therapy or greater) (Parenteral) by the first half of 2027

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top